Patents by Inventor Jay A. Markwalder
Jay A. Markwalder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9765018Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.Type: GrantFiled: July 1, 2014Date of Patent: September 19, 2017Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb CompanyInventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, David K. Williams, Amy C. Hart, Jennifer Inghrim
-
Patent number: 9758492Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.Type: GrantFiled: August 26, 2014Date of Patent: September 12, 2017Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Syngene International LimitedInventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, Shefali Srivastava, David K. Williams, Libing Chen
-
Publication number: 20170231999Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.Type: ApplicationFiled: May 2, 2017Publication date: August 17, 2017Inventors: James Aaron Balog, Emily Charlotte Cherney, Weiwei Guo, Audris Huang, Jay A. Markwalder, Steven P. Seitz, Weifang Shan, David K. Williams, Natesan Murugesan, Susheel Jethanand Nara, Saumya Roy, Soodamani Thangavel, Ramesh Kumar Sistla, Srinivas Cheruku, Srinivasan Thangathirupathy, Yadagiri Kanyaboina, Nagalakshmi Pulicharla
-
Publication number: 20170197973Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.Type: ApplicationFiled: March 27, 2017Publication date: July 13, 2017Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Emily Charlotte Cherney, Weifang Shan, Audris Huang
-
Patent number: 9675571Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.Type: GrantFiled: March 12, 2014Date of Patent: June 13, 2017Assignee: Bristol-Myers Squibb CompanyInventors: James Aaron Balog, Audris Huang, Bin Chen, Libing Chen, Steven P. Seitz, Amy C. Hart, Jay A. Markwalder
-
Publication number: 20170143649Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.Type: ApplicationFiled: February 1, 2017Publication date: May 25, 2017Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Steven P. Seitz, Emily Charlotte Cherney, Liping Zhang, Weifang Shan, Weiwei Guo, Audris Huang
-
Patent number: 9643972Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.Type: GrantFiled: November 5, 2015Date of Patent: May 9, 2017Assignee: Flexus Biosciences, Inc.Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Emily Charlotte Cherney, Weifang Shan, Audris Huang
-
Patent number: 9598422Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.Type: GrantFiled: November 5, 2015Date of Patent: March 21, 2017Assignee: Flexus Biosciences, Inc.Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Steven P. Seitz, Emily Charlotte Cherney, Liping Zhang, Weifang Shan, Weiwei Guo, Audris Huang
-
Publication number: 20160297805Abstract: There are disclosed compounds that are inhibitors of EZH2, pharmaceutical compositions containing said compounds and methods of treating hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases utilizing the compounds of the invention.Type: ApplicationFiled: November 18, 2014Publication date: October 13, 2016Inventors: Steven P. Seitz, Jay A. Markwalder, Ashok Vinayak Purandare
-
Publication number: 20160289171Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.Type: ApplicationFiled: April 1, 2016Publication date: October 6, 2016Inventors: James Aaron Balog, Emily Charlotte Cherney, Weiwei Guo, Audris Huang, Jay A. Markwalder, Steven P. Seitz, Weifang Shan, David K. Williams, Natesan Murugesan, Susheel Jethanand Nara, Saumya Roy, Soodamani Thangavel, Ramesh Kumar Sistla, Srinivas Cheruku, Srinivasan Thangathirupathy, Yadagiri Kanyaboina, Nagalakshmi Pulicharla
-
Publication number: 20160200674Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.Type: ApplicationFiled: August 26, 2014Publication date: July 14, 2016Applicant: Bristol-Myers Squibb CompanyInventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, Shefali Srivastava, David K. Williams, Libing Chen
-
Publication number: 20160143870Abstract: There are disclosed compounds of Formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.Type: ApplicationFiled: July 10, 2014Publication date: May 26, 2016Inventors: Jay A Markwalder, James Aaron Balog, Audris Huang, Steven P Seitz
-
Publication number: 20160137653Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.Type: ApplicationFiled: November 5, 2015Publication date: May 19, 2016Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Steven P. Seitz, Emily Charlotte Cherney, Liping Zhang, Weifang Shan, Weiwei Guo, Audris Huang
-
Publication number: 20160137652Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.Type: ApplicationFiled: November 5, 2015Publication date: May 19, 2016Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Emily Charlotte Cherney, Weifang Shan, Audris Huang
-
Publication number: 20160137595Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.Type: ApplicationFiled: July 1, 2014Publication date: May 19, 2016Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, David K. William, Amy C. Hart, Jennifer Inghrim
-
Publication number: 20160022619Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.Type: ApplicationFiled: March 12, 2014Publication date: January 28, 2016Inventors: James Aaron Balog, Audris Huang, Bin Chen, Libing Chen, Steven P. Seitz, Amy C. Hart, Jay A. Markwalder
-
Patent number: 8791257Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) pyrrolotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.Type: GrantFiled: March 30, 2011Date of Patent: July 29, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Jay A. Markwalder, Brian E. Fink, Ashvinikumar V. Gavai, Liqi He, Soong-Hoon Kim, Steven P. Seitz
-
Publication number: 20130023514Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) pyrrolotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.Type: ApplicationFiled: March 30, 2011Publication date: January 24, 2013Applicant: Bristol-Myers Squibb CompanyInventors: Jay A. Markwalder, Brian E. Fink, Ashvinikumar V. Gavai, Liqi He, Soong-Hoon Kim, Steven P. Seitz
-
Patent number: 7659281Abstract: Compounds are provided of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia and dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis wherein variables A and B are defined herein.Type: GrantFiled: April 24, 2007Date of Patent: February 9, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Philip D. Stein, Steven P. Seitz, David J. Carini, Yan Shi, Jeffrey A. Robl, Jay A. Markwalder, Chunhong He
-
Publication number: 20070249583Abstract: Compounds are provided of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia and dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis wherein A is chosen from B is chosen from wherein the variables R1 to R7, m, n, are as defined herein. A method for treating the above diseases employing the above compounds is also provided.Type: ApplicationFiled: April 24, 2007Publication date: October 25, 2007Inventors: Philip D. Stein, Steven P. Seitz, David J. Carini, Yan Shi, Jeffrey A. Robl, Jay A. Markwalder, Chunhong He